gp100 (529-537)

gp100 (529-537) is a synthetic peptide fragment derived from the human glycoprotein 100 (gp100), a melanocyte differentiation antigen prominently expressed in melanoma cells. This nonapeptide corresponds to amino acid residues 529 through 537 of the gp100 protein sequence and is widely recognized for its immunological significance in the study of tumor antigens. Owing to its well-characterized epitope sequence, gp100 (529-537) serves as an indispensable research tool for investigating antigen presentation, T cell recognition, and peptide-MHC interactions in the context of melanoma and cellular immunology. Its defined sequence and reproducible synthesis make it a valuable asset for controlled experimental systems in both basic and translational research settings.

Immunological research: The gp100 (529-537) peptide is extensively utilized in immunological studies focused on antigen-specific T cell responses. As a well-defined epitope recognized by cytotoxic T lymphocytes (CTLs), particularly in the context of HLA-A*0201, it enables researchers to dissect the cellular mechanisms underlying immune recognition of melanoma-associated antigens. By employing this peptide in in vitro assays, scientists can evaluate CTL activation, proliferation, and cytokine production, thereby elucidating the dynamics of tumor-specific immune responses and facilitating the development of immunotherapeutic strategies.

Peptide-MHC binding studies: The defined sequence of this nonapeptide makes it an ideal substrate for examining peptide binding affinity and stability with major histocompatibility complex (MHC) class I molecules. Researchers frequently use gp100 (529-537) to investigate the structural and biochemical determinants of peptide-MHC interaction, which is central to understanding antigen processing and presentation. Such studies provide critical insights for optimizing epitope selection in vaccine design and for predicting immunogenicity in silico and in vitro.

Assay development: As a model antigenic peptide, gp100 (529-537) is instrumental in the development and validation of T cell-based assays, including ELISPOT, intracellular cytokine staining, and tetramer-based flow cytometry. Its use allows for the standardized assessment of antigen-specific T cell populations in various experimental systems, supporting both preclinical and translational research. The peptide's reproducibility and immunological relevance contribute to the generation of robust, quantitative data in cellular immunology workflows.

Peptide synthesis and modification studies: The sequence of gp100 (529-537) is frequently employed as a template for the synthesis of peptide analogs and modified derivatives. Researchers utilize these analogs to probe structure-activity relationships, enhance immunogenicity, or modulate peptide-MHC binding characteristics. Such studies are fundamental for the rational design of improved peptide-based probes, immunogens, or inhibitors, advancing both basic peptide chemistry and applied immunological research.

Epitope mapping and validation: The well-defined nature of this peptide makes it a valuable reference in epitope mapping experiments. By using gp100 (529-537) in competitive binding assays or T cell recognition studies, investigators can confirm the specificity of T cell receptors (TCRs) and validate the immunodominance of this epitope within the broader gp100 antigen. These applications are essential for characterizing T cell repertoires, refining antigen selection, and supporting the development of targeted immunological reagents for research use.

1. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

2. Emu oil in combination with other active ingredients for treating skin imperfections

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

5. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum